Benitec Biopharma is currently engaged in commercialising a technology that was developed at the CSIRO, that we think is truly exquisite. It has the capability to be almost disruptive in the way diseases are treated.
We call the technology DNA directed RNA interference, or DDRNAi for short. The technology has the capability to cure a wide range of of human diseases, typically with one single injection.
The company is dual-listed, here in Australia on the ASX and back in August this year the company completed a raising in the United States and a listing on the Nasdaq.
